Literature DB >> 6390640

Focal hepatic candidiasis: a distinct clinical variant of candidiasis in immunocompromised patients.

L S Tashjian, J S Abramson, J E Peacock.   

Abstract

Focal hepatic candidiasis is a distinct clinical variant of candidiasis in immunocompromised hosts. Although affected patients may exhibit previous evidence of extra-hepatic candidal infection, manifestations of disease at the time hepatic involvement is documented are localized to the liver. Five cases of focal hepatic candidiasis in immunocompromised patients were diagnosed antemortem in the past 15 months at our institution. Clinical, laboratory, and radiologic findings from those five patients, as well as from 20 additional cases reported in the medical literature, are reviewed. Patients with focal hepatic candidiasis had fever unresponsive to antimicrobial therapy, prominent gastrointestinal symptoms and signs, elevated levels of alkaline phosphatase, and hepatic, with or without accompanying splenic, defects noted on abdominal computed tomography. Liver biopsy usually revealed yeast and/or hyphal forms, but cultures were frequently negative. Response to therapy occurred in only 13 (59%) of 22 assessable patients. The apparent increasing incidence of focal hepatic candidiasis may be due to the recent use of more intensely cytotoxic chemotherapies for cancer.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6390640     DOI: 10.1093/clinids/6.5.689

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  13 in total

1.  Successful treatment of focal hepatic candidiasis with liposomal amphotericin B.

Authors:  B O'Connell; G Crotty; M T Cafferkey; R Stephens; G S McDonald; S R McCann
Journal:  Ir J Med Sci       Date:  1992-12       Impact factor: 1.568

2.  Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.

Authors:  T J Walsh; P Whitcomb; S Piscitelli; W D Figg; S Hill; S J Chanock; P Jarosinski; R Gupta; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  Evaluation of a murine model of hepatic candidiasis.

Authors:  G T Cole; K T Lynn; K R Seshan
Journal:  J Clin Microbiol       Date:  1990-08       Impact factor: 5.948

Review 4.  Fungal infections of the immunocompromised host: clinical and laboratory aspects.

Authors:  C E Musial; F R Cockerill; G D Roberts
Journal:  Clin Microbiol Rev       Date:  1988-10       Impact factor: 26.132

5.  Hepatosplenic candidasis, a fatal disease?

Authors:  A Loeliger; M van Leeuwen; M Rozenberg-Arska; A W Dekker
Journal:  Infection       Date:  1992-11       Impact factor: 3.553

6.  Candidal liver abscesses and cholecystitis in a 37-year-old patient without underlying malignancy.

Authors:  Chung-Hsu Lai; Hsin-Pai Chen; Te-Li Chen; Chang-Phone Fung; Cheng-Yi Liu; Shou-Dong Lee
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

Review 7.  Candidiasis.

Authors:  F Meunier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

8.  Successful second allogeneic bone marrow transplantation in a relapsed acute myeloid leukemia patient with fungal liver abscess.

Authors:  J Tanaka; M Kasai; N Masauzi; M Watanabe; A Matsuura; K Morii; Y Kiyama; T Naohara; T Higa; S Hashino
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

9.  Hepatosplenic candidiasis, a late manifestation of Candida septicaemia in neutropenic patients with haematologic malignancies.

Authors:  M von Eiff; M Essink; N Roos; W Hiddemann; T Büchner; J van de Loo
Journal:  Blut       Date:  1990-04

10.  Hepatic and splenic abscesses--a common complication of intensive chemotherapy of acute myeloid leukemia (AML). A prospective study.

Authors:  N Grois; G Mostbeck; R Scherrer; A Chott; I Schwarzinger; M Muhm; P Bettelheim; C Forstinger; K Laczika; P A Kyrle
Journal:  Ann Hematol       Date:  1991-07       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.